Blazing Star Merger Sub completes Walgreens debt tender offer
Jennifer Doudna, a director at Tempus AI , Inc. (NASDAQ:TEM), recently sold 625 shares of the company’s Class A common stock. The shares were sold at a price of $48.12 each, amounting to a total transaction value of $30,075. Following this sale, Doudna holds 25,740 shares directly. The transaction was executed under a pre-established Rule 10b5-1 trading plan, which had been adopted on August 28, 2024.
In other recent news, Tempus AI has reported a strong fourth-quarter performance for 2024, with a revenue increase of 35.8% year-over-year, reaching $700 million. Despite this growth, the company posted an earnings per share (EPS) of -0.18. Tempus AI has also completed the acquisition of Deep 6 AI and Ambry Genetics, which is expected to enhance their capabilities in AI-driven research platforms and genomic profiling. Stifel analysts have maintained a Hold rating on Tempus AI, with a $65 price target following the earnings report. Meanwhile, JPMorgan downgraded Tempus AI from Overweight to Neutral but raised the price target to $55, citing a slight revenue shortfall in non-core business.
Tempus AI has projected a revenue of $1.24 billion for 2025, which includes contributions from Ambry Genetics. The company anticipates a 30% growth in its core business, slightly below JPMorgan’s estimate of 34%. The recent developments in Tempus AI’s business include the launch of Olivia AI, a personal health app, and the extension of their agreement with Google (NASDAQ:GOOGL) for another five years. These strategic moves are aimed at expanding their reach and enhancing the deployment of AI applications in healthcare.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.